Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Ming‐Tain Lai et al.|The Lancet HIV|2018Cited by 145
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J. Dore, Thomas Podsadecki, Brian Conway et al.|Journal of Hepatology|2015Cited by 68
A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infectionRichard Elion, Javier Szwarcberg, José Ramón Arribas et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2013Cited by 41